Progress14 Jan 2021 06:44
All going 'to plan' and he's comfortable with where they are. Phase 3 will start 'imminently' (they will RNS 1st dose) and once started will roll out quickly. He's well aware of not 'missing' the 2nd wave of patients. There is ongoing global interest, with 20 countries lined up (they won't launch in all initially). Key is less starting the trial but in making sure it recruits quickly and completes. IMMINENTLY TICK
NEXT
Synairgen's Investigational New Drug (IND) application to the FDA to evaluate SNG001 as a treatment for patients with COVID-19, has been cleared, enabling Synairgen to initiate its SG018 trial in the US. Furthermore, the FDA has awarded SNG001 Fast Track status, enhancing the ability of Synairgen to interact with the FDA and shortening review timelines.
ACTIV-2
Looming
Poetry in motion
They are currently scoping to be able to increase drug supply significantly from current plans, so they will be ready to upscale should it get approval, and also strengthens their hand in any future negotiations
What's not to like